Figure 4 from NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma

Le résumé fourni par la source

In vivo analysis of intracranial GL261 tumor immune microenvironment composition following STING and NLRP3 inflammasome activation. A, Mice received intracranial injection of 5.0 × 104 GL261 cells, then were treated with 5 μg of cdGMP and/or nigericin, and tumor-bearing hemispheres harvested 48 hours following treatment for spectral flow cytometry analysis. B, Live CD45+ cell densities reported as cells per tumor-bearing hemisphere. C, Live CD45+ cell frequency as a fraction of total single cells. D–G, Overall composition and fold changes of cell densities vs. vehicle-treated tumors for analyzed CD45+ (D and E) myeloid and (F and G) lymphoid cell populations. Error bars represent mean ± SEM. Statistical significance was calculated using the Student t test. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. cDC1, type 1 conventional dendritic cells; Neg., negatively.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.